Accordingly, NIM-1324 is a prime candidate for a first-in-class oral therapeutic in the treatment ... from systemic lupus erythematosus (SLE) patients and provided protection from clinical disease ...

Objective To assess the efficacy of anifrolumab, a type-1 interferon receptor subunit-1 monoclonal antibody, in treating refractory cutaneous lupus erythematosus (CLE ... Superficial calcinosis cutis ...

with a 30%-plus market share in the oral psoriasis category. The company is also developing the drug for follow-up indications including psoriatic arthritis and systemic lupus erythematosus (SLE).

Interface dermatitis (ID) is a reaction characterized by an itchy rash with small, water-filled blisters. It is often associated with an autoimmune disorder such as lupus or dermatomyositis. Interface ...

Systemic lupus can be mild or severe. Cutaneous lupus erythematosus This form of lupus is limited to the skin and can cause many types of rashes and lesions. Drug-induced lupus erythematosus This is a ...

Specific and nonspecific rashes associated with antibodies to Ro/SS-A are often related to subacute cutaneous lupus erythematosus (SCLE). Typically, lesions specific to SCLE do not itch and may ...

Immune cells called monocytes produce a key inflammatory protein called interleukin-1 beta (IL-1β) through an unconventional pathway in patients with systemic lupus erythematosus, commonly referred to ...

Biomarkers that reliably identify or even predict disease manifestations in systemic lupus erythematosus (SLE) are needed. In a recent issue of the Clinical Journal of the American Society of ...

Systemic lupus erythematosus (SLE) and inflammatory bowel disease (IBD, a group of intestinal disorders that cause inflammation of the digestive tract) share a common set of microbiome features that ...

The drug is being tested in patients with the most common form of lupus, systemic lupus erythematosus, where the patient's immune system attacks the body's own tissues and potentially leads to ...